Pharmaceutical

Ocuphire and Opus Genetics merge to develop IRD gene therapy

Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs).

Oct 24, 2024 - 04:00
Ocuphire and Opus Genetics merge to develop IRD gene therapy
Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs).
Read the original article

Tags:

Previous Article

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

Next Article

FDA approves Alvotech and Teva’s SELARSDI for new indications

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Roche wins first approval for subcutaneous Tecentriq

Roche wins first approval for subcutaneous Tecentriq

Aug 30, 2023

STAT+: Generic group sues Minnesota over a drug pricing transparency law it calls an ‘unconstitutional overreach’

STAT+: Generic group sues Minnesota over a drug pricing...

Jul 6, 2023

STAT+: Mystery of allergic memory gets closer to answer: a rare group of B cells

STAT+: Mystery of allergic memory gets closer to answer...

Feb 7, 2024